RET and thyroid gland carcinoma: While selective RET inhibitors show potent activity in brain metastases of lung and thyroid cancer patients (267, 274), the emergence of therapeutic resistance to RET inhibitors suggests activation of additional or alternative pathways that circumvent pharmacological inhibition of RET.